Literature DB >> 27401938

Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?

Alain Braillon1, Joel Lexchin2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27401938     DOI： 10.1016/j.healthpol.2016.06.012

Source DB:  PubMed          Journal:  Health Policy        ISSN： 0168-8510            Impact factor:   2.980


× No keyword cloud information.
  3 in total

1.  Innovation and off-label use, the French case and more.

Authors:  Alain Braillon; Joel Lexchin
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

2.  Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

Authors:  Roojin Habibi; Joel Lexchin; Barbara Mintzes; Anne Holbrook
Journal:  Br J Clin Pharmacol       Date:  2017-08-19       Impact factor: 4.335

3.  The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.

Authors:  Bo Wang; David M Studdert; Ameet Sarpatwari; Jessica M Franklin; Joan Landon; Aaron S Kesselheim
Journal:  PLoS One       Date:  2017-04-07       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.